Breast Cancer

In the metastatic breast cancer sphere, 2 chemotherapy agents have come to the forefront: capecitabine, for metastatic breast cancer, and eribulin, for triple-negative breast cancer.

Elisavet Paplomata, MD, discusses the clinical impact of tucatinib in HER2-positive breast cancer.

Treatment options for triple-negative breast cancer are historically limited; however, recent developments regarding the use of targeted therapies and various combination regimens have broadened the treatment spectrum and ushered in new clinical approaches.

Neratinib was shown to have a numerical overall survival benefit in addition to improvements in invasive disease-free survival and central nervous system recurrence in patients with HER2-positive, hormone receptor–positive, early stage breast cancer.

Sara M. Tolaney, MD, MPH, discusses the phase 2 APT and ATEMPT trials in stage I HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the evolution of treatment in HER2-positive breast cancer.

The Breast Cancer Research Foundation has awarded a 1-year, $175,000 research grant to Yale Cancer Center to study reducing re-excisions for breast conserving therapy for women following surgery for breast cancer.

In our exclusive interview, Antoinette R. Tan, MD, of Atrium Health, discusses the FDA approval of the fixed-dose combination of pertuzumab and trastuzumab in HER2-positive breast cancer and highlights the results of the pivotal FeDeriCa trial.

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.

Erika P. Hamilton, MD, discusses ​the final overall survival results from the ​randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive​, HER2-negative metastatic breast cancer.

Aditya Bardia, MD, MPH, discusses the results of the randomized phase 3 ASCENT trial in previously treated, metastatic triple-negative breast cancer.

In our exclusive interview, Dr. Tripathy discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.

Frontline fulvestrant in combination with palbociclib demonstrated an improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone in patients with endocrine-sensitive hormone receptor-positive, HER2-negative metastatic breast cancer, which met the primary end point of the phase 2 FLIPPER trial.